Blair William & Co. IL and O Shaughnessy Asset Management LLC have increased their shares in Takeda Pharmaceutical Company, while Capital Research Global Investors and others reduced their holdings. Despite a steep decline and a lukewarm operating profit, Takeda's stock has recently attracted the attention of value investors, spurring optimism about a potential rebound. The company is reportedly expanding its pipeline, even though concerns about growth persist. Its release of an Employee Incentive Plan and share issuance has also buoyed enthusiasm. Institutional and retail investors are highly enthusiastic about Takeda, illustrated by large ownership percentages. The upcoming dividend is expected to surpass last year's, helped by a profitable licensing deal with ImmunoGen and a strong quarterly report. The company's shares have recently gapped up, making it an attractive dividend stock. Finally, acquisitions such as a $62 billion Shire deal marked a significant spike in Takeda's growth journey.
